1 Min Read
March 29 (Reuters) - Mylan:
* Spokeswoman says company has no comment at this point on its U.S. FDA application for generic copy of GlaxoSmithKline’s Advair
* For more on this story see Further company coverage: (Reporting by Ben Hirschler)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.